At the conclusion of this activity, participants should be better prepared to:
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
The following individuals have no relevant financial relationships with commercial interests to disclose:Linda Bosserman, MD; AneesChagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C); Frankie Ann Holmes, MD, FACP; Fred Kass, MD; Michael Lewis, PhD; Rita Nanda, MD; Debra Patt, MD, MPH, MBA; Melvin Silverstein, MD, FACS; Frank Vicini, MD, FACR; Jeffrey Weitzel, MD
The staff of PER®: Ann C. Lichti, CHCP; Susan Peck, PhD; Michael Perlmutter, PharmD, MS
The following individuals have relevant financial relationships with commercial interests to disclose:
Kathy Albain, MD, FACP, FASCO Consultant: Genomic Health; Rowan Chlebowski, MD, PhD Research Support: National Institutes of Health; Consultant: Novartis, Genentech, Amgen, Genomic Health, Pfizer, Novo Nordisk; Speakers Bureau: Novartis, Genentech; Anthony Elias, MD Research Support: Clinical trial support from multiple companies including Medivation and Astellas Pharma; Consultant: Genentech; Mohammad Jahanzeb, MD, FACP Research Support: Lilly, AbbVie, Genentech, Novartis; Consultant: Novartis; Eleftherios Mamounas, MD, MPH, FACS Consultant: Genomic Health, Celgene, Pfizer; Speakers Bureau: Genomic Health, Genentech/Roche; Ingrid Mayer, MD, MSCI Research Support: Novartis, Clovis Oncology; Advisory Board Member: Novartis; Gordon Mills, MD, PhD Research Support: Adelson Medical Research Foundation, AstraZeneca, Critical Outcome Technologies, GlaxoSmithKline, Illumina; Consultant: AstraZeneca, Blend Therapeutics, Critical Outcome Technologies, HanAl Bio Korea, Nuevolution, Novartis, Pfizer, Provista Diagnostics, Roche, SignalChem Lifesciences, Symphogen, Tau; Shareholder: Catena Pharmaceuticals, PTV Ventures, Spindletop Ventures; Pamela Munster, MD - Research Support: Merck, Novartis, Biomarin, Merrimack Pharmaceuticals, Calithera, Celgene; Consultant: Huya Bioscience International; Joyce O'Shaughnessy, MD Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda Pharmaceutical, MedFusion; Lori Pierce, MD, FASTRO Shareholder: PFS Genomics (Founder’s Shares); Royalties: UpToDate; Lajos Pusztai, MD, DPhil Research Support: Merck, Genentech, Seattle Genetics, Foundation Medicine; Consultant: Pfizer, Celgene, BioTheranostics. Merck; Hope Rugo, MD, FACS Research Support: GlaxoSmithKline, Genentech/Roche, Merck, Novartis, Plexxikon, Eisai, OBI, Amgen, Pfizer, Macrogenics, Lilly; Speakers Bureau: Genomic Health; Joseph Sparano, MD Consultant: AstraZeneca, Novartis, Celgene, Genentech/Roche, Eli Lilly, Celldex Therapeutics; Shareholder: MetaStat;Sara Tolaney, MD, MPH Research Support: Genentech; Consultant: Lilly, Pfizer, Genentech; Douglas Yee, MD Research Support: I-SPY2 Trial Grant
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY